Skip to content
PeptidesDirect
Healing & Recovery

TB-500

Quick answer

TB-500 is a synthetic peptide derived from thymosin beta-4, studied in preclinical research for its role in promoting tissue repair and angiogenesis. It remains a research-use-only compound without FDA approval for medical use.

What is TB-500?

TB-500 is a synthetic peptide representing an active region of thymosin beta-4, a naturally occurring protein involved in cellular repair and regeneration. It was developed to mimic the biological activities of thymosin beta-4, particularly its ability to promote tissue healing and angiogenesis.

Originally isolated from thymosin beta-4, TB-500 focuses on a specific sequence that retains key functional properties, facilitating its use in laboratory research settings. It is chemically characterized by the molecular formula C38H68N10O14 and a molecular weight of 889.0 g/mol, with a well-defined structure enabling analytical quantification in biological samples.

In the research context, TB-500 has been extensively studied in vitro and in animal models to elucidate its effects on wound healing, angiogenesis, and extracellular matrix remodeling. These studies aim to better understand its potential mechanisms and applications in tissue regeneration and repair, although human clinical data are currently limited.

Researchers investigate TB-500 to explore its utility as a therapeutic peptide in orthopaedic and regenerative medicine fields, focusing on its ability to modulate cellular pathways involved in recovery from injury and tissue degeneration.

Key Benefits & Mechanisms

  • Enhanced Tissue RepairPreclinical studies indicate that TB-500 facilitates tissue repair by promoting cellular migration and proliferation in damaged tissues. This effect is linked to its capacity to modulate actin dynamics, which is critical for wound closure and regeneration processes.
  • Promotion of AngiogenesisTB-500 has been shown to stimulate the formation of new blood vessels in experimental models, a key step in effective healing. Angiogenesis supports nutrient and oxygen delivery to injured sites, thereby accelerating tissue recovery.
  • Extracellular Matrix RemodelingResearch demonstrates that TB-500 influences extracellular matrix components through integrin-mediated pathways, facilitating remodeling and structural integrity restoration in healing tissues. This remodeling is essential for functional repair of damaged musculoskeletal structures.
  • Non-Cytotoxic Metabolites with Biological ActivityInvestigations into TB-500 metabolism reveal that its primary metabolites lack cytotoxicity and may retain or enhance wound healing activity. These findings suggest a complex pharmacodynamic profile that supports its regenerative potential in vitro and in vivo.
  • Potential Application in Orthopaedic InjuriesTB-500 is studied alongside other peptides for its potential to improve outcomes in musculoskeletal injuries by enhancing tissue regeneration and reducing recovery time. Although human clinical evidence is sparse, preclinical data support its role as a candidate for orthopaedic research.

Mechanism of action

TB-500 primarily acts by promoting angiogenesis and facilitating tissue repair through modulation of cellular processes critical for regeneration. It influences actin binding and cytoskeletal dynamics, which enhances cell migration and proliferation at injury sites. Additionally, TB-500 affects extracellular matrix remodeling via integrin-mediated signaling pathways, supporting structural tissue recovery. While these mechanisms are well-characterized in preclinical models, direct clinical evidence in humans remains limited, underscoring the need for further research to fully elucidate its biological effects and therapeutic potential.

Research Summary

The 2026 review "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions" highlights TB-500 among wound-healing peptides that promote angiogenesis and extracellular matrix remodeling, emphasizing promising preclinical results but noting the absence of robust clinical trials. The 2026 article "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians" discusses TB-500 as a derivative of thymosin beta-4 with demonstrated preclinical efficacy in tissue repair and angiogenesis, while also underscoring the limited human orthopaedic data and the need for rigorous clinical validation. The 2024 study "Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro" developed analytical methods to quantify TB-500 and its metabolites, revealing that certain metabolites exhibit significant wound healing activity without cytotoxicity, thereby providing valuable insights into its metabolism and biological effects in preclinical models.

Dosing in Research Literature

Research literature on TB-500 dosing primarily involves in vitro experiments and animal studies, with dose ranges varying depending on the model and experimental design. Precise dosing protocols for humans are not established due to the lack of clinical trials. In animal models, TB-500 has been administered in varying concentrations to assess wound healing and angiogenic effects, often via injection routes. These studies focus on pharmacokinetics, metabolite profiling, and biological activity rather than defining standardized doses. Given the current research context, dosing remains exploratory and highly variable, emphasizing the necessity for further pharmacological and toxicological studies to determine safe and effective dose parameters.

The figures above describe doses reported in published or preclinical research, provided for context only. This is not medical advice or a dosing recommendation, and these compounds are not approved for human use.

Common Stacks

BPC-157 Co-researched with TB-500 for their complementary roles in promoting tissue repair and angiogenesis, BPC-157 is another peptide studied for enhancing musculoskeletal healing and recovery in preclinical settings. GHK-Cu GHK-Cu is investigated alongside TB-500 due to its properties in extracellular matrix remodeling and wound healing, potentially synergizing to improve regenerative outcomes in laboratory models. CJC-1295 CJC-1295, a growth hormone secretagogue, is studied in combination with TB-500 for its role in stimulating satellite cell repair and IGF-1 signaling, which may complement TB-500’s tissue repair mechanisms in research applications.

Frequently asked questions about TB-500

Is TB-500 approved by the FDA for medical use?

TB-500 is not approved by the U.S. Food and Drug Administration (FDA) for any medical applications. It is classified as a research peptide and is intended for laboratory and preclinical research use only.

What biological processes is TB-500 studied for?

TB-500 is primarily studied for its ability to promote angiogenesis, tissue repair, and wound healing. It is investigated in preclinical models for its effects on cellular migration, extracellular matrix remodeling, and regeneration of damaged tissues.

How does TB-500 exert its mechanism of action?

TB-500 acts by modulating actin dynamics and integrin-mediated signaling pathways, which enhances cell migration, proliferation, and extracellular matrix remodeling. These processes collectively support angiogenesis and tissue regeneration in preclinical studies.

Can TB-500 be combined with other peptides in research?

Yes, TB-500 is often researched in combination with peptides such as BPC-157, GHK-Cu, and CJC-1295 to explore synergistic effects on tissue repair, angiogenesis, and growth hormone-related pathways in experimental settings.

How should TB-500 be stored and handled in a research environment?

As a research peptide, TB-500 should be stored according to manufacturer guidelines, typically in a lyophilized form at low temperatures to maintain stability. Proper handling protocols to prevent contamination and degradation are essential in laboratory settings.

Are there known metabolites of TB-500 with biological activity?

Research has identified several metabolites of TB-500, such as Ac-LKKTE, which exhibit wound healing activity without cytotoxic effects, suggesting that metabolites may contribute to its overall biological profile in preclinical models.

Why is TB-500 of interest in orthopaedic research?

TB-500 is of interest due to its potential to enhance musculoskeletal tissue repair and angiogenesis, which are critical processes in recovery from orthopaedic injuries. Preclinical data support its role as a candidate for further investigation in regenerative medicine.

Legal & research status: Research use only — not approved by the FDA for human use. Sold and discussed for laboratory and research use only, not for human consumption.

Research use only All content is provided for informational and research purposes only and is not medical advice. Peptides referenced are sold and discussed for laboratory and research use only, not for human consumption. Consult a licensed physician before making any health decision.